Rotigotine transdermal patch: A guide to its use in Parkinson's disease and restless leg syndrome

Once-daily administration of the rotigotine transdermal patch (Neupro ®) is effective in treating patients with early Parkinson's disease (as monotherapy), advanced Parkinson's disease (in combination with levodopa), inadequate morning motor control despite antiparkinsonian treatment (mostly in combination with levodopa), and moderate to severe idiopathic restless legs syndrome. Rotigotine is generally well tolerated, with the most common treatment-emergent adverse events being application-site reactions, gastrointestinal disturbances, somnolence and headache. © 2013 Springer International Publishing Switzerland.